Newswise — ROCHESTER, Minn. — Mayo Clinic researchers have discovered that people with major depressive disorder and a history of attempted suicide have distinct biomarkers that correlate with their response to antidepressant therapy. The new findings, published in Frontiers Pharmacology, are key to individualized treatment strategies and early identification of patients who are at the highest risk for suicide.
For the study, the researchers used multi-omics technologies — specifically, metabolomics and genomics — to analyze samples from 350 patients with major depressive disorder. They compared samples of patients with and without a history of suicide attempt(s) and found distinct blood-based multi-omics signatures between the two groups, despite all patients having the same diagnosis of major depressive disorder.
Nearly 700,000 people worldwide die by suicide every year, along with 10-20 times as many non-fatal suicide attempts, according to the World Health Organization. A prior suicide attempt is the highest risk factor for suicide in the general population.
“Evaluating suicidal patients can be challenging because clinical risk assessments are inherently subjective and major depressive disorder has high degrees of variability,” says Paul Croarkin, D.O., M.S., a psychiatrist in Mayo Clinic’s Department of Psychiatry and Psychology, and senior investigator of the study. "Our study lays a foundation for advancing the prognostic potential of this disease and enhancing patient outcomes that use both biological and digital biomarkers."
The team found that variations in the genes CLOCK and ARNTL differentiate in patients with and without a prior suicide attempt. Both genes are related to the circadian rhythm, which regulates critical functions in the body, including behavior, metabolism, hormone levels and sleep. These specific gene variations are also associated with lower antidepressant response and remission rates.
Metabolomics is the study of metabolites, which are substances created when the body breaks down food, drugs or its own tissue. Genomics is the study of genes, which can influence enzymes that are crucial for metabolizing medicines. While individually they explain aspects of biological processes, analyzing them jointly has potential of revealing interactions that were previously not studied.
Altogether, multi-omics is a combination of two or more "omics" approaches. Additional multi-omics examples include proteomics, the study of proteins; epigenomics, the study of epigenetic changes on DNA; and transcriptomics, the study of RNA molecules.
By simultaneously evaluating the genome and metabolome, the researchers discovered biological signatures that could not be found by the genome or metabolome alone.
The study is part of ongoing efforts at Mayo Clinic to understand the biology of suicidality to improve diagnostic approaches, treatments, and outcomes for patients with depression and other mood disorders.
The study was led by researchers within Mayo Clinic's Department of Molecular Pharmacology and Experimental Therapeutics in the Center for Individualized Medicine and the Department of Psychiatry and Psychology. It demonstrates team science using large datasets to address challenges of individualizing medicine practices of globally devastating diseases.
Acknowledgments
This work is supported by the Harry C. and Debra A. Stonecipher Predoctoral Fellowship at the Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic Summer Undergraduate Research Fellowship, National Science Foundation (NSF) under grant IIS-2041339; R01 MH113700, R01 MH124655, Blue Gator Foundation, and the Mayo Clinic Center for Individualized Medicine.
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
RSS